Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Therapeutic cancer vaccines and combination immunotherapies involving vaccination.

Nguyen T, Urban J, Kalinski P.

Immunotargets Ther. 2014 Oct 6;3:135-50. doi: 10.2147/ITT.S40264. eCollection 2014. Review.

2.

Protection against Paracoccidioides brasiliensis infection in mice treated with modulated dendritic cells relies on inhibition of interleukin-10 production by CD8+ T cells.

da Costa TA, Di Gangi R, Martins P, Longhini AL, Zanucoli F, de Oliveira AL, Stach-Machado DR, Burger E, Verinaud L, Thomé R.

Immunology. 2015 Nov;146(3):486-95. doi: 10.1111/imm.12526. Epub 2015 Sep 21.

3.

Cancer immunotherapy using a potent immunodominant CTL epitope.

Song L, Yang MC, Knoff J, Sun ZY, Wu TC, Hung CF.

Vaccine. 2014 Oct 21;32(46):6039-48. doi: 10.1016/j.vaccine.2014.09.021. Epub 2014 Sep 20.

4.

Engagement of SLAMF2/CD48 prolongs the time frame of effective T cell activation by supporting mature dendritic cell survival.

Kis-Toth K, Tsokos GC.

J Immunol. 2014 May 1;192(9):4436-42. doi: 10.4049/jimmunol.1302909. Epub 2014 Mar 26.

5.

Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L.

Llopiz D, Huarte E, Ruiz M, Bezunartea J, Belsúe V, Zabaleta A, Lasarte JJ, Prieto J, Borrás-Cuesta F, Sarobe P.

Oncoimmunology. 2013 Dec 1;2(12):e27009. Epub 2013 Dec 5.

6.

Selective induction of CTL helper rather than killer activity by natural epitope variants promotes dendritic cell-mediated HIV-1 dissemination.

Mailliard RB, Smith KN, Fecek RJ, Rappocciolo G, Nascimento EJ, Marques ET, Watkins SC, Mullins JI, Rinaldo CR.

J Immunol. 2013 Sep 1;191(5):2570-80. doi: 10.4049/jimmunol.1300373. Epub 2013 Aug 2.

7.

Analysis, Isolation, and Activation of Antigen-Specific CD4(+) and CD8(+) T Cells by Soluble MHC-Peptide Complexes.

Schmidt J, Dojcinovic D, Guillaume P, Luescher I.

Front Immunol. 2013 Jul 30;4:218. doi: 10.3389/fimmu.2013.00218. eCollection 2013.

8.

P3 mAb: An Immunogenic Anti-NeuGcGM3 Antibody with Unusual Immunoregulatory Properties.

Martínez D, Rodríguez N, Griñán T, Rondón T, Vázquez AM, Pérez R, Hernández AM.

Front Immunol. 2012 Apr 26;3:94. doi: 10.3389/fimmu.2012.00094. eCollection 2012.

9.

Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL.

Immunol Res. 2011 Aug;50(2-3):235-47. doi: 10.1007/s12026-011-8224-z.

10.

Cooperation between molecular targets of costimulation in promoting T cell persistence and tumor regression.

Zhao B, Song A, Haque R, Lei F, Weiler L, Xiong X, Wu Y, Croft M, Song J.

J Immunol. 2009 Jun 1;182(11):6744-52. doi: 10.4049/jimmunol.0804387.

11.

Dendritic cell-based therapeutic cancer vaccines: what we have and what we need.

Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R.

Future Oncol. 2009 Apr;5(3):379-90. doi: 10.2217/fon.09.6. Review.

12.

Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines.

Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P.

Cancer Immunol Immunother. 2009 Aug;58(8):1329-36. doi: 10.1007/s00262-008-0648-5. Epub 2009 Jan 21.

13.

Memory CD8+ T cells protect dendritic cells from CTL killing.

Watchmaker PB, Urban JA, Berk E, Nakamura Y, Mailliard RB, Watkins SC, van Ham SM, Kalinski P.

J Immunol. 2008 Mar 15;180(6):3857-65.

Supplemental Content

Support Center